The EMJ Podcast: Insights For Healthcare Professionals

Innovations in the treatment of endometriosis and adenomyosis In this episode, the host Saranya Ravindran speaks with Tommaso Falcone about transformative developments in reproductive health, including the evolution of endometriosis research, the promise of robotic surgery, and the global expansion of gynaecologic care. From debunking myths about fertility to reflecting on cross-continental medical practice, this episode explores the future of women's health through the eyes of a pioneering clinician and researcher. Timestamps: 00:00 – Barriers to early endometriosis detection 09:16 – Treating adenomyosis and fertility impact 12:10 – Global health innovation in emerging markets 16:05 – The first uterus transplant

Robotic revolution in reproductive surgery. In this episode, the host Saranya Ravindran speaks with Tommaso Falcone about transformative developments in reproductive health, including the evolution of endometriosis research, the promise of robotic surgery, and the global expansion of gynaecologic care. From debunking myths about fertility to reflecting on cross-continental medical practice, this episode explores the future of women's health through the eyes of a pioneering clinician and researcher. Timestamps: 00:20 – What's next in gynaecologic robotic surgery? 06:46 – Falcone's pioneering research 16:44 – Three wishes for healthcare

Lydia Scarfò is a Physician Scientist at the B-cell Neoplasia Unit and an Assistant Professor at Università Vita-Salute San Raffaele, Milan, Italy.   She is involved in both clinical and pre-clinical studies, including being a co-investigator in over 20 clinical trials in haematological malignancies, including chronic lymphocytic leukaemia.  Timestamps:  0:00 – Introduction  1:14 – Quickfire questions  7:31 – Haematology inspiration  9:08 – STIL loss  11:42 – Splenic marginal zone lymphoma  13:03 – Novel targeted therapies for chronic lymphocytic leukaemia  17:35 – Covalent BTK inhibitors   19:30 – Chemo-free approach for hairy cell leukaemia  22:20 – Recent advances, challenges, and opportunities  25:58 – Three wishes 

Global Perspectives and Leadership in Gynaecology In this episode, the host Saranya Ravindran speaks with Tommaso Falcone about transformative developments in reproductive health, including the evolution of endometriosis research, the promise of robotic surgery, and the global expansion of gynaecologic care. From debunking myths about fertility to reflecting on cross-continental medical practice, this episode explores the future of women's health through the eyes of a pioneering clinician and researcher. Timestamps: 00:00 – Comparing gynaecology globally 03:20 – The evolution of endometriosis research 05:30 – Breakthroughs and hopes for a cure

In this episode, the host Saranya Ravindran speaks with Tommaso Falcone about transformative developments in reproductive health, including the evolution of endometriosis research, the promise of robotic surgery, and the global expansion of gynaecologic care. From debunking myths about fertility to reflecting on cross-continental medical practice, this episode explores the future of women's health through the eyes of a pioneering clinician and researcher. Timestamps: 00:00 – Introduction 01:05 – Quickfire round 05:12 – ‘Yes or no' segment

This episode offers expert insights Dr. Aravindhan Veerapandiyan, MD. Exploring Becker Muscular Dystrophy (BMD), covering early signs, diagnostic challenges, disease progression, and current management approaches. It also explores care transitions, multidisciplinary involvement, and unmet needs in the BMD care landscape.

In this second episode of our lung cancer miniseries, Jonathan Sackier is joined by David Baldwin, a leading expert in screening, epidemiology, and policy. Baldwin reflects on national screening programmes, groundbreaking trials, and how AI, big data, and evidence-based guidelines are reshaping lung cancer care. Timestamps: 00:00 – Introduction 03:17 – Key takeaways from the UKLS trial 11:10 – Boosting participation in screening studies 17:04 – The Targeted Lung Health Check programme 23:30 – Understanding large datasets in lung cancer epidemiology 32:44 – AI and big data in lung cancer imaging 41:43 – Shaping national guidelines 47:47 – Are we doing enough to prevent lung cancer? 53:06 – Baldwin's three wishes for healthcare

In the second part of this special episode of Onc Now, Jonathan Sackier continues his thrilling conversation with Bradley Monk, a leading gynaecologic oncologist, with an in-depth discussion of the DUO-E trial, Monk's most impactful Society of Gynecologic Oncology (SGO) insights, and the integration of AI into the clinic. Timestamps:  00:00 – Introduction  00:40 – Quickfire questions  06:19 – Inspiration  08:31 – Molecular basis of cancer treatment  12:12 – DUO-E trial design  14:12 – Barriers to 4-drug regimen approval and access  20:01 – Most impactful SGO insights  21:10 – AI integration  24:03 – Three wishes  26:30 – Outro 

In the third and final episode of our miniseries on infectious disease diagnostics, Jonathan sits down with global diagnostics leader Rosanna Peeling, Professor and Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine. Together, they explore the life-saving role of diagnostics in global health, from battling STDs to confronting COVID-19, and examine how equitable access, social innovation, and regulatory reform can transform disease control and pandemic preparedness.   Timestamps: 00:00 – Introduction 06:09 – Rosanna's interest in microbiology 08:12 – The IDC's work 10:52 – Funding for diagnostics 13:30 – Diagnostic testing in low-resource settings 18:21 – Chlamydia research 24:19 – Regulatory approval challenges 29:35 – Social innovation 34:08 – Clinician adaptation 37:10 – Current diagnostic innovations 40:30 – Rosana's three wishes for healthcare

Rafael Fonseca is a distinguished Haematologist at Mayo Clinic, specialising in multiple myeloma and related plasma cell disorders. He earned his medical degree at Universidad Anáhuac in Mexico, and went on to complete his residency in Internal Medicine at the University of Miami, Florida, USA followed by a Hematology and Oncology fellowship at Mayo Clinic in Rochester, Minnesota, USA.     Timestamps  01:44 – Quickfire questions  07:25 – CAR-T cell therapy  10:48 – Anti-CD38 antibodies  13:31 – Minimal residual disease  14:30 – Bispecific antibodies  15:31 – Antibody-drug conjugates  19:04 – ASCO 2025  21:24 – Genetic discoveries  26:28 – Fonseca's three wishes 

In this episode, Jonathan Sackier kicks off a special miniseries on lung cancer with Haval Balata, Consultant Respiratory Physician at Manchester University NHS Foundation Trust. From the Manchester Lung Health Check to robotic bronchoscopy, Balata shares insights into pioneering early detection efforts, the challenge of public misconceptions, and innovations reshaping lung cancer screening and diagnosis. Timestamps: 03:12 – Inspiration to specialise 04:09 – Early diagnosis barriers 08:02 – Manchester Lung Health Check 14:10 – Robot-assisted bronchoscopy 19:24 – Public misconceptions 28:57 – Risk stratification & follow-up 34:24 – Innovations in early detection 37:10 – Hopes for the future 41:22 – Three healthcare wishes

In this two-part series host Jonathan Sackier is joined by Bradley Monk, a pioneering figure in gynaecologic oncology. In Part 1, they discuss key updates from the European Society of Gynaecological Oncology (ESGO) Congress, including the updated ESGO-ESTRO-ESP endometrial cancer guidelines and the latest results from the KEYLYNK-001 study in ovarian cancer. With reflections from his three-decade career, Monk provides actionable takeaways for clinicians and researchers alike. Stay tuned for Part 2, where they delve into insights from SGO 2025.  Timestamps:  00:00 - Quickfire questions 04:55 - Career milestones 07:10 - ESGO 2025 standout sessions 09:52 - KEYLYNK-001 trial & takeaways 13:52 - New endometrial cancer staging   

In this bonus episode, join EMJ host Dr Hannah Moir as she speaks with our two urological experts, Dr Todd Linsenmeyer and Dr Chris Harding. They discuss recent advances in day-to-day technologies for intermittent catheterisation, covering innovations and advancements in catheter technology aimed at improving the user experience.

In this three-part series, Jonathan Sackier sits down with Isabelle Amigues, rheumatologist and founder of UnabridgedMD, a direct rheumatology practice in Denver, Colorado, USA. Together, they discuss the importance of hope in patient care and the inspiration behind starting her own practice. Timestamps: 1:12 – A typical consultation 7:50 – Advice for clinicians

In this three-part series, Jonathan Sackier sits down with Isabelle Amigues, rheumatologist and founder of UnabridgedMD, a direct rheumatology practice in Denver, Colorado, USA. Together, they discuss the importance of hope in patient care and the inspiration behind starting her own practice. Timestamps: 0:14 – The power of hope for patients 1:08 – Opening her own practice  

In this three-part series, Jonathan Sackier sits down with Isabelle Amigues, rheumatologist and founder of UnabridgedMD, a direct rheumatology practice in Denver, Colorado, USA. Together, they discuss the importance of hope in patient care and the inspiration behind starting her own practice. Timestamp: 2:27 – The origins of ‘Hope Driven by Science'

In this episode of Hema Now, host Jonathan Sackier is joined by Paolo Gallipoli, Clinical Reader at the Centre for Haemato-Oncology at Barts Cancer Institute, to break down the biology, onset, and treatment of myeloid leukaemias. They detail common misconceptions about myeloid leukaemias, explain the differences between chronic myeloid leukaemia and acute myeloid leukaemia, and discuss Gallipoli's own research in the field, with a view towards future developments.  Timestamps  01:34 – Quickfire questions  06:55 – Potential careers  08:43 – Common misconceptions  11:34 – Best advice received  13:43 – Adaptive metabolic changes  16:45 – Chronic myeloid leukaemia vs acute myeloid leukaemia  19:20 – Recent publication  22:55 – Clonal hematopoiesis    27:13 – Treatment obstacles  29:18 – Future developments  31:01 – Gallipoli's three wishes 

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care. 01:47 – Interstitial Lung Disease 08:25 – Evolution of Rheumatology 11:39 – Wishes for Healthcare

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care 01:49 – Polymyalgia Rheumatica 05:59 – Vascular Ultrasound 09:11 – Immune Ageing

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care. 00:22 – Mortality Patterns 08:57 – JAK Inhibitors

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Joan Carles, Head of Section for the Genitourinary, Central Nervous System, Sarcomas and Tumours of Unknown Origin Unit at Vall d'Hebron University Hospital. Carles discusses breakthroughs in genitourinary cancer and sarcoma treatment, including anti-angiogenic therapies, overcoming resistance, and the role of genetic polymorphisms in personalised medicine.  Timestamps:     00:00 – Introduction   01:56 – Anti-angiogenic therapies  05:03 – Treatment resistance  07:53 – Genetic polymorphisms  09:02 – Sarcoma treatments  11:16 – Novel drugs  15:22 – Oncology societies  18:00 – Carles' three wishes for healthcare 

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease. Timestamps: 00:00 – Healthtech innovation 03:02 – Biohacking's future 09:20 – Three healthcare wishes   

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.  Timestamps: 00:00 – Resilience Health's impact 04:30 – Gut–brain connection 12:00 – Immune optimisation   

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.  Timestamps:  02:00 – Career evolution 06:45 – Holistic medicine explained 

In this episode of Hema Now, Diu Nguyen joins Jonathan Sackier to discuss breakthroughs in acute myeloid leukaemia (AML) research. From RNA-binding proteins to the future of stem cell-targeted therapies, Nguyen shares the translational goals of her lab and what's on the horizon in AML diagnosis and treatment.    Timestamps:  01:20 – Quickfire Insights  03:32 – AML Breakthroughs  04:47 – Leukaemia Surprise  06:42 – Alternate Pathways  07:54 – RNA Differences  12:08 – Diagnostics Future  14:03 – RBMX Spotlight  20:21 – Targeted Therapies  27:07 – Treatment Barriers  31:32 – Three Wishes 

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences. Topics discussed include: Current confusion about the clinical heterogeneity within the intermediate-risk patient group The best way to select adequate intravesical therapy for this group The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy *References Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/ Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.

This is a non-promotional podcast funded and developed by AbbVie for healthcare professionals only. The content of this podcast is correct at the time of recording, which is December 2024. The views expressed in this podcast are those of the individual speakers and do not necessarily reflect the view of AbbVie or EMJ If you are listening to this podcast through a podcast app, please note that any advertisements you may hear are not affiliated with this podcast or AbbVie in any way. To stop receiving podcast notifications, please unsubscribe from this series in your podcast player. The Post-Stroke Spasticity Classification System was created and funded by AbbVie with the assistance of a group of international experts in the field of Post-Stroke Spasticity, utilising both published risk factors and their own clinical experience. BONT-AA-00049-MC April 2025

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials.  Timestamps:    00:17 – Digital health equity  06:00 – Podcasts in medicine  07:59 – Three cardiology wishes 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:    00:21 – Biomarker disparities  04:52 – Norway trial challenges  07:15 – Boosting trial engagement 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:  02:06 – Skiing & heart  04:02 – Blix award impact  07:51 – Heart failure biomarkers 

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Janice Walshe, Consultant Medical Oncologist at St Vincent's University Hospital, Dublin, Ireland. They explore the economic realities of cancer diagnostics, fertility preservation in patients with breast cancer, and the impact of international collaboration on the future of clinical trials.  Timestamps:    00:00 – Introduction  03:25 – Economic disparities and oncology care in Ireland  07:20 – Neoadjuvant therapy for HER2-positive breast cancer  10:13 – Spotlight on invasive lobular carcinoma  12:36 – Fertility preservation in breast cancer  15:20 – Menopause after cancer  19:09 – The latest clinical trials in Ireland  21:50 – International trials and research projects  23:50 – Walshe's three wishes for healthcare 

In this episode of Hema Now, Jonathan Sackier is joined by John Riches, Clinical Reader in Cancer Immunometabolism at the Barts Cancer Institute and Honorary Consultant Haemato-oncologist. They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies.  Timestamps:      00:00 – Introduction  01:46 – Riches' journey into haematology  03:42 – What is T cell exhaustion?  07:06 – The key role of metabolism in lymphoma  09:33 - Richter's syndrome  13:17 – Breakthroughs in immunotherapy  20:27 – The challenges of translational research  25:39 – B cells in autoimmune diseases  28:16 – The potential of breath biopsy  32:58 – Riches' three wishes for healthcare 

In the second episode of our miniseries on infectious disease diagnostics, Jonathan is joined by molecular epidemiologist Rodney Rohde, Regents' Professor at Texas State University, USA. Together, they explore diagnostic innovations in the fight against antimicrobial resistance, gaps in zoonotic disease detection, and the persistent challenge of vaccine hesitancy. Timestamps: 00:00 – Introduction 01:45 – Breakthroughs in molecular diagnostics 08:30 – Diagnostic tools to combat superbugs 14:18 – Can bacteriophages replace antibiotics? 19:04 – Controlling rabies and hantavirus 28:33 – Diagnostic successes and failures from COVID-19 35:22 – How do we address vaccine hesitancy? 44:10 – Preparing for the next pandemic 47:03 – Rohde's three wishes for healthcare

In this episode, Jonathan Sackier is joined by Philip Hamann, Consultant Rheumatologist at North Bristol NHS Trust, UK. Known for his engaging TEDx talks and innovative work with AI-driven healthcare apps, Hamann discusses how big data, personalised medicine, and a holistic approach are revolutionising care for patients with rheumatoid arthritis.  Timestamps:  00:00 – Introduction   01:01 – Using humour to communicate science   06:02 – ‘Living with Rheumatoid Arthritis': Hamann's award-winning app  14:43 – The cost of personalised medicine  19:07 – Real-world use of the app  26:05 – Importance of real-time data in rheumatology  33:10 – What does holistic care really mean?  40:07 – Hamann's three wishes for healthcare 

In this episode, host Jonathan Sackier speaks with Alexander Spira about cutting-edge advances in lung and colorectal cancer, including EGFR and KRAS-targeted therapies. They also discuss Spira's leadership in oncology research, his thoughts on the evolving ‘town-gown' dynamic in US medicine, and his hopes for the future of cancer care.  Timestamps:  00:00 – Introduction 01:50 – Most memorable family travel adventure 03:30 – What inspired you to go into oncology 05:49 – Three recent publications in lung cancer 07:02 – Real-world data on colorectal cancer 08:15 – Sex/gender differences in non-small cell lung cancer 11:53 – The science of KRAS mutations and drug development 15:07 – Accelerating diagnostics and access to therapies 17:13 – The ‘town-gown' debate in American healthcare 18:09- Three Wishes 

In this episode, Jonathan Sackier is joined by Adrian Owen, Professor of Cognitive Neuroscience and Imaging at the University of Western Ontario. They explore Owen's groundbreaking research on consciousness in vegetative states, the ethical questions raised by his work, and the cutting-edge technology that has changed our understanding of the brain.  Timestamps:  00:00 – Introduction  02:46 – Taking one album on a desert island  04:03 – A groundbreaking discovery about vegetative states  06:58 – Owen's bestseller: ‘Into the Gray Zone'   11:18 – Where is the border between life and death?  15:40 – Cutting-edge technologies for brain imaging   20:11 – Applications of fMRI and EEG  24:41 – Does brain-training work?  31:09 – Implications for life support and end-of-life care  36:00 – Owen's three wishes for healthcare   

This week, Jonathan is joined by Shaji Kumar, an expert in hematology and oncology, particularly multiple myeloma, who has made significant contributions to both clinical and translational science. Timestamps:  (00:00) – Introduction   (02:23) – Drug combinations and myeloma biology  (08:34) – Treating newly diagnosed multiple myeloma  (17:24) – Quadruplet regimens   (23:09) – Clinical trials for plasma cell malignancies  (28:04) – The bone marrow microenvironment in multiple myeloma  (30:29) – “Blind men and an elephant”  (33:58) – Kumar's three wishes for healthcare   

This podcast series was sponsored by Theramex UK who had no input in the content which was developed by EMJ. The speakers were selected by Theramex and received honorarium. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Theramex or EMJ. Please refer to local marketing authorisation and prescribing practices for guidance. The Effect of HRT on Brain Function and Mental Health. - Episode 3 - Brain health expert Rossella Nappi joins Hannah Moir to discuss the effect of MHT on brain function and mental health. In this podcast series, we focus on women's health and the impact of menopause. Our experts explore the role and long-term impact of menopausal hormone therapy (MHT), otherwise referred to as hormone replacement therapy (HRT), on our heart, bones, and brain.

In this episode of the EMJ Podcast, Jonathan Sackier sits down with Jose Alexander, Clinical Microbiologist and Director of Microbiology at AdventHealth Orlando, to explore the cutting edge of infectious disease diagnostics. From next-generation sequencing to rapid tests for brain-eating amoeba, Alexander shares insights into the latest innovations shaping the field, the fight against antimicrobial resistance, and the future of microbiology diagnostics. Timestamps: 00:00 – Introduction 03:55 – Alexander's introduction to microbiology 05:42 – Developing a rapid test for a brain-eating amoeba 09:40 – Where is this amoeba found? 12:13 – Next-generation sequencing in infectious disease 14:36 – Streptococcus pneumoniae serotype/genotype service 17:06 – Vaccine hesitancy 19:03 – Antimicrobial resistance 22:02 – The discovery of a novel variant of Klebsiella pneumoniae 24:32 – The clinical use of bacteriophages 27:01 – The future of the field 28:41 – Alexander's three wishes for healthcare

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Stephen Chan, Clinical Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong, to discuss groundbreaking trials in hepatobiliary cancers, the role of diet in chronic liver disease, and the future of liver cancer care.  Timestamps:    00:00 – Introduction  02:09 – CARES-310 trial for liver cancer   4:33 – Camrelizumab + rivoceranib versus sorafenib  7:07 – Prevention and early detection of liver cancer   10:30 – Impact of lifestyle and diet on liver disease  12:38 – KEYNOTE-966 trial for biliary tract cancer  14:45 – Alternative strategies for liver cancer treatment  17:14 – Key initiatives of the International Liver Cancer Association  19:26 – Chan's three wishes for healthcare 

In this episode of the EMJ Podcast, Jonathan Sackier sits down with Faranak Kamangar, Chair of Dermatology at Palo Alto Medical Foundation and President of the San Francisco Dermatological Society, to discuss the future of AI and telehealth in dermatology.    Timestamps:  00:00 – Introduction  01:41 – DermGPT: bringing AI to dermatology  07:35 – Why telehealth is here to stay  11:15 – Targeted immunotherapies: what's new?  16:57 – Using media to drive education  22:39 – Precision medicine in melanoma  27:15 – Kamangar's podcast ‘The Future of Dermatology'  31:05 – Three wishes for healthcare  

Timestamps:      00:00- Introduction  00:41- Health benefits of yoga and mindfulness   02:34- The potential of AI in hematology  04:23- Transfusion dependence in myelodysplastic syndromes  08:13- The fascinating field of apheresis  10:56- How to provide high-quality, affordable healthcare?  15:44- Regulatory T cells in hematologic malignancies  19:55- CAR T clinical trials: regulatory insights  22:57- EBMT initiatives  30:06- Latest breakthroughs in amyloidosis   34:50- Reducing patient fear through education 

Supported by Gilead Sciences Europe Ltd who provided funding for this content and is intended for healthcare professionals. Gilead Sciences Europe Ltd was not involved in the creation of this content. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Gilead Sciences Europe Ltd or EMJ. Note that not all treatments discussed in this episode may have received market approval. Please refer to your local marketing authorisation and prescribing practices for guidance. The speakers received honoraria. Tune into this episode hosted by Hannah Moir, which discusses what PBC is, and key takeaways from the AASLD conference.

In this episode of the EMJ Podcast, Jonathan Sackier speaks with Rachel Rubin, a urologist and sexual medicine specialist, about the need for patient-centred care, the importance of multidisciplinary approaches, and breaking the stigma around sexual health. Rubin also shares insights into improving medical education and advancing healthcare policies to better support sexual medicine.  Timestamps:  00:00 - Introduction  02:51 - Importance of patient-centred care in sexual medicine  06:05 - Benefits of a multidisciplinary approach to sexual health  11:45 - Gaps in sexual medicine education and training  15:20 - Addressing stigma in sexual health  23:21 - Reframing menopause in clinical practice  29:15 - Training in male and female sexual medicine  38:35 - Gender reassignment and gender-affirming care  47:45 - Three wishes for the future of sexual healthcare 

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Sebastian Stintzing, Head of Department of Medicine, Division of Hematology, Oncology, and Cancer Immunology, Charité - Universitäetsmedizin Berlin, Germany. They discuss the most promising developments in gastrointestinal oncology, with particular focus on the role of personalised medicine in metastatic colorectal cancer treatment.  Timestamps:    00:00 – Introduction  03:04 – Impactful developments in gastrointestinal oncology  08:53 – Issues with funding clinical trials  14:17 – Designing trials and the importance of patient advocacy   17:11 – Translational biomarker programs  19:58 – Treatment strategies for RAS wild-type tumours  22:28 – The FIRE-4.5 study on mutant metastatic colorectal cancer  29:50 – Genetic profiling and epigenomics  33:12 – Precision medicine and immune oncology in GI cancers  34:52 – Colorectal cancer in younger adults  34:54 – Raising awareness for early screening of GI cancers 

This podcast series was sponsored by Theramex UK who had no input in the content which was developed by EMJ. The speakers were selected by Theramex and received honorarium. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Theramex or EMJ. Please refer to local marketing authorisation and prescribing practices for guidance. Long-term Benefits of Use of MHT/HRT on the Heart, Bones, and Brain - Episode 2 - Bone expert Kassim Javaid joins Hannah Moir to explore the impact of MHT on our bones. In this podcast series, we focus on women's health and the impact of menopause. Our experts explore the role and long-term impact of menopausal hormone therapy (MHT), otherwise referred to as hormone replacement therapy (HRT), on our heart, bones, and brain.

This podcast series was sponsored by Theramex UK who had no input in the content which was developed by EMJ. The speakers were selected by Theramex and received honorarium. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Theramex or EMJ. Please refer to local marketing authorisation and prescribing practices for guidance. Long-term Benefits of Use of MHT/HRT on the Heart, Bones, and Brain - Episode 1 - Heart expert Yassir Javaid joins Hannah Moir to discuss the role of MHT in cardiovascular health. In this podcast series, we focus on women's health and the impact of menopause. Our experts explore the role and long-term impact of menopausal hormone therapy (MHT), otherwise referred to as hormone replacement therapy (HRT), on our heart, bones, and brain.

In this episode, Jonathan Sackier welcomes Andrew Blauvelt, a distinguished dermatologist and leading expert in immunodermatology. They discuss groundbreaking advancements in psoriasis treatment, including the role of high-dose biologics in achieving deep remission and how IL-23 inhibition is transforming long-term disease management. Timestamps: (00:00) – Introduction (02:25) – A recent knockout study (17:22) – The wider applications of biologic treatments (19:40) – Deep remission in psoriasis (27:20) – The next frontier in psoriasis research (32:36) – Barriers to research breakthroughs (36:11) – What's on the horizon for dermatology research? (41:37) – Andrew's three wishes for healthcare

This week, Jonathan is joined by Xavier Leleu, world-renowned expert in multiple myeloma, Waldenström's macroglobulinemia, and amyloidosis. The pair discuss groundbreaking advances in clinical trials and the future of myeloma immunotherapy.   Timestamps:  (00:00)-Introduction  (00:59)-Clinical trial breakthroughs in transplant-ineligible myeloma  (03:38)-Minimal residual disease: a key endpoint   (05:21)-Rethinking therapeutic strategies in myeloma   (10:58)-Challenges in late-line myeloma therapies   (13:54)-T-cell-engaging bispecific antibodies   (17:41)-Waldenström's macroglobulinemia and amyloidosis  (21:50)-What's next in multiple myeloma treatment?  (24:43)-Xavier's three wishes for healthcare